Blume-Jensen Peter 4
4 · Acrivon Therapeutics, Inc. · Filed Mar 4, 2025
Insider Transaction Report
Form 4
Blume-Jensen Peter
DirectorPresident and CEO
Transactions
- Award
Stock Option (Right to Buy)
2025-03-01+390,390→ 390,390 totalExercise: $5.31Exp: 2035-02-28→ Common Stock (390,390 underlying) - Award
Stock Option (Right to Buy)
2025-03-01+140,540→ 140,540 total(indirect: See Footnote)Exercise: $5.31Exp: 2035-02-28→ Common Stock (140,540 underlying)
Footnotes (3)
- [F1]Twenty-five percent (25%) of the shares subject to the option vest on March 1, 2026, and the remaining shares subject to the option vest in 36 substantially equal monthly installments thereafter, in each case subject to the Reporting Person's continuous service through each vesting date.
- [F2]These securities are held by President and CEO, Dr. Peter Blume-Jensen, who is also Dr. Kristina Masson's spouse. Dr. Masson disclaims beneficial ownership of such securities except to the extent of her pecuniary interest therein.
- [F3]These securities are held by co-founder and EVP, Dr. Kristina Masson, who is also Dr. Blume-Jensen's spouse. Dr. Blume-Jensen disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.